Skip To Main Content

Important Safety Information

You or your child should not get NUVAXOVID if you had a severe allergic reaction to a previous dose of NUVAXOVID or to any of its ingredients.

There is a remote chance that the vaccine could cause a severe allergic reaction, which would usually occur within a few minutes to one hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include: difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body and/or dizziness and weakness

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received NUVAXOVID. The chance of having this occur is very low. You should seek medical attention right away if you or your child have any of the following symptoms after receiving the vaccine: chest pain; shortness of breath; feelings of having a fast-beating, fluttering, or pounding heart.

Other side effects reported in clinical trials and/or post-approval use of NUVAXOVID include: Injection site reactions (pain/tenderness, swelling, redness and itching), fatigue or generally feeling unwell, muscle pain, headache, joint pain, nausea, vomiting, fever, chills, allergic reactions such as hives and swelling of the face, swollen lymph nodes, paresthesia (unusual feeling in the skin such as tingling or a crawling feeling), and hypoesthesia (decreased feeling or sensitivity, especially in the skin)

Indication

NUVAXOVID is a vaccine to protect against COVID-19 for people who are:

  • 65 years of age and older, or
  • 12 years through 64 years of age at high risk for severe COVID-19

Vaccination with NUVAXOVID may not protect all people who receive the vaccine.

NUVAXOVID does not contain SARS-CoV-2, the virus that causes COVID-19. NUVAXOVID cannot give you or your child COVID-19.

Learn more about Sanofi's commitment to fighting counterfeit drugs.